Abpro Holdings, Inc 10-Q for FY2025 Q2
Abpro Holdings, Inc. (ABPO)
About this 10-Q
Abpro Holdings, Inc filed this 10-Q on August 13, 2025, covering the quarter ended June 30, 2025 (FY2025 Q2).
Headline figures
Quarter ended June 30, 2025, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Net loss
- $2.98M
- compared with a net loss of $2.44M a year earlier
- Diluted EPS
- -$0.05
- compared with -$0.13 a year earlier
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(MARK ONE)
For the quarter ended
or
For the transition period from __________ to __________
Commission file number:
(Exact Name of Registrant as Specified in Its Charter)
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
100 Summit Drive
Burlington, MA 01803
(Address of principal executive offices)
(Issuer’s telephone number)
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The | ||||
| The |
Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days.
Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large, accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large, accelerated filer | ☐ | Accelerated filer | ☐ |
| ☒ | Smaller reporting company | ||
| Emerging growth company |
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
As of August 11, 2025, there were 81,150,000 and
ABPRO HOLDINGS, INC.
FORM 10-Q FOR THE QUARTER ENDED JUNE 30, 2025
TABLE OF CONTENTS
i
PART I - FINANCIAL INFORMATION
Item 1. Interim Financial Statements.
ABPRO HOLDINGS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands except for share and per share data)
(Unaudited)
| June 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash | $ | $ | ||||||
| Accounts receivable | ||||||||
| Prepaid expenses and other current assets | ||||||||
| Forward purchase agreement asset | ||||||||
| Restricted cash | ||||||||
| Total current assets | ||||||||
| Property and equipment, net | ||||||||
| Right-of-use asset - operating lease | ||||||||
| Security deposits | ||||||||
| Patents, net | ||||||||
| SEPA put rights asset | ||||||||
| Total assets | $ | $ | ||||||
| Liabilities and stockholders’ deficit | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued expenses | ||||||||
| Excise taxes payable | ||||||||
| Operating lease liability, current | ||||||||
| Income taxes payable | ||||||||
| Note payable | ||||||||
| Notes payable – related parties | ||||||||
| Convertible notes | ||||||||
| Embedded derivative liability | ||||||||
| Total current liabilities | ||||||||
| Commitments and Contingencies (Note 9) | ||||||||
| Stockholders’ deficit: | ||||||||
| Preferred stock, $ | ||||||||
| Common stock, $ | ||||||||
| Treasury stock, | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total Abpro Holdings, Inc.’s stockholders’ deficit | ( | ) | ( | ) | ||||
| Non-controlling interest | ||||||||
| Total stockholders’ deficit | ( | ) | ( | ) | ||||
| Total liabilities and stockholders’ deficit | $ | $ | ||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
1
ABPRO HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands except share and per share data)
(Unaudited)
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | $ | $ | $ | ||||||||||||
| General and administrative | ||||||||||||||||
| Total operating expenses | ||||||||||||||||
| Loss from operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other (expense) income: | ||||||||||||||||
| Other income | ||||||||||||||||
| Change in fair value of forward purchase agreement asset | ( | ) | ||||||||||||||
| Change in fair value of SEPA put rights asset | ( | ) | ( | ) | ||||||||||||
| Change in fair value of embedded derivative liability | ( | ) | ( | ) | ||||||||||||
| Loss on settlement of convertible notes | ( | ) | ( | ) | ||||||||||||
| Interest income | ||||||||||||||||
| Interest expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Total other (expense) income, net | ( | ) | ( | ) | ( | ) | ||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Net loss per share, basic and diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Weighted averages shares outstanding | ||||||||||||||||
| Weighted average shares outstanding - basic and diluted | ||||||||||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
2
ABPRO HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT
(in thousands except share and per share data)
(Unaudited)
| Series
A Redeemable, Convertible Preferred Stock | Series
B Convertible Preferred Stock | Series
C Convertible Preferred Stock | Series
D Convertible Preferred Stock | Series
E Convertible Preferred Stock | Series
F Convertible Preferred Stock | Total Convertible Preferred Stock | Common Stock | Treasury Stock | Additional Paid-In | Accumulated | Total Abpro’s Stockholders’ | Non-controlling | Total Stockholders’ | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | Deficit | Interest | Deficit | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balances, as of December 31, 2024 | $ | $ | $ | $ | $ | $ | $ | $ | | ( | ) | $ | $ | $ | ( | ) | $ | ( | ) | $ | | $ | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Common stock issued for services | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Warrants issued to related party lender | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-based compensation | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | - | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balances, as of March 31, 2025 | - | - | - | - | - | - | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-based compensation | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Common stock issued upon conversion of convertible notes | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | - | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balances, as of June 30, 2025 | $ | $ | $ | $ | $ | $ | $ | $ | ( | ) | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Series A Redeemable, Convertible Preferred Stock | Series B Convertible Preferred Stock | Series C Convertible Preferred Stock | Series D Convertible Preferred Stock | Series E Convertible Preferred Stock | Series F Convertible Preferred Stock | Total Convertible Preferred Stock | Common Stock | Treasury Stock | Additional Paid-In | Accumulated | Total Abpro’s Stockholders’ | Non-controlling | Total Stockholders’ | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | Deficit | Interest | Deficit | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balances, as of December 31, 2023 | $ | $ | $ | $ | $ | $ | $ | $ | | ( | ) | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | $ | | $ | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Vesting of restricted stock units | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-based compensation | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balances, as of March 31, 2024 | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Vesting of restricted stock units | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-based compensation | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | - | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balances, as of June 30, 2024 | $ | $ | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
3
ABPRO HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands except share and per share data)
(unaudited)
| For the Six Months Ended June 30, | ||||||||
| 2025 | 2024 | |||||||
| Cash Flows from Operating Activities: | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization expense | ||||||||
| Share-based compensation | ||||||||
| Amortization of operating lease right-of-use assets | ||||||||
| Noncash interest expense | ||||||||
| Loss on settlement of convertible notes | ||||||||
| Other income (see Note 2) | ( | ) | ( | ) | ||||
| Amortization of debt discount | ||||||||
| Change in fair value of forward purchase agreement asset | ||||||||
| Change in fair value of SEPA put rights asset | ||||||||
| Change in fair value of embedded derivative liability | ||||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | ( | ) | ( | ) | ||||
| Prepaid expenses and other current assets | ( | ) | ( | ) | ||||
| Accounts payable | ( | ) | ||||||
| Accrued expenses | ||||||||
| Income taxes payable | ||||||||
| Operating lease liability | ( | ) | ( | ) | ||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| Cash Flows from Financing Activities: | ||||||||
| Proceeds from settlement of Forward Purchase Agreement | ||||||||
| Proceeds from issuances of debt | ||||||||
| Proceeds from issuance of Note payable | ||||||||
| Payments on Note payable | ( | ) | ||||||
| Payment of offering costs | ( | ) | ||||||
| Repayment of finance lease liabilities | ( | ) | ||||||
| Net cash provided by financing activities | ||||||||
| Net change in cash and restricted cash | ( | ) | ( | ) | ||||
| Cash and restricted cash - beginning of period | ||||||||
| Cash and restricted cash - end of period | $ | $ | ||||||
| Supplemental disclosure of cash flow information and non-cash transactions: | ||||||||
| Interest paid | $ | $ | ||||||
| Fair value of common stock issued for services | $ | $ | ||||||
| Common stock issued in settlement of convertible notes and embedded derivative liability | $ | $ | ||||||
| Deferred offering costs included in accounts payable | $ | $ | ||||||
| Reclassification of residual value guarantees under finance lease to accrued expense | $ | $ | ||||||
| As reported within the unaudited condensed consolidated balance sheets: | ||||||||
| Cash | $ | $ | ||||||
| Restricted cash | ||||||||
| Total cash and restricted cash as presented in the balance sheet | $ | $ | ||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
4
ABPRO HOLDINGS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(Amounts in thousands, except share and per share data)
| 1. | Organization and Description of the Business |
Organization
Abpro Holdings, Inc. and its subsidiaries, (the “Company”) is a biotechnology company dedicated to developing next-generation antibody therapeutics to improve the lives of patients with severe and life-threatening diseases. The Company is focused on the development of novel antibodies using its proprietary discovery and engineering platforms, primarily in the areas of immuno-oncology, ophthalmology and infectious disease.
On November 13, 2024 (the “Closing Date”), Atlantic Costal Acquisition Corp. II (“ACAB”) consummated a merger (the “Merger”) pursuant to the terms of the Merger Agreement, dated as of December 11, 2023 (the “Merger Agreement”) by and among Abpro Corporation (“Legacy Abpro”), ACAB, and Abpro Merger Sub Corp., a Delaware corporation (“Merger Sub”) and wholly owned subsidiary of ACAB prior to the Closing Date. Pursuant to the Merger Agreement, on the Closing Date, (i) ACAB changed its name to “Abpro Holdings, Inc.” (“New Abpro”), and (ii) Merger Sub merged with and into Legacy Abpro, with Legacy Abpro as the surviving company in the Merger (such transactions, the “Merger,” and, collectively with the other transactions described in the Merger Agreement, the “Reverse Recapitalization”). Shares of the New Abpro common stock commenced trading on the Nasdaq Capital Market on November 14, 2024.
After giving effect to the Merger, Legacy Abpro became a wholly owned subsidiary of the Company. The Merger was accounted for as a reverse recapitalization in accordance with U.S. GAAP, and under this method of accounting, ACAB was treated as the acquired company for financial reporting purposes and Legacy Abpro was treated as the acquirer. Operations prior to the Merger are those of Legacy Abpro. Unless otherwise noted, the Company has retroactively adjusted all common and preferred share and related price information to give effect to the Exchange Ratio as set forth in the Merger Agreement. The “Company” refers to Abpro Holdings, Inc. and its subsidiaries, including Abpro Corporation, prior to and subsequent to the Merger. Legacy Abpro is the accounting acquirer in the Merger and, as such, the condensed consolidated financial statements for the three months and six months ended June 30, 2024 present operations of Legacy Abpro prior to the Merger Date.
Refer to Note 3 — Merger for further details of the Merger.
Risks and Uncertainties
The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of more advanced or effective therapies, dependence on key executives, protection of and dependence on proprietary technology, compliance with government regulations and ability to secure additional capital to fund operations. Programs currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure, and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.
Going Concern
The Company is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. Through June 30, 2025, the Company has funded its operations mainly through equity and debt financings, including the proceeds from the issuance of shares under SEPA (see Notes 12 and 17), as well as from the Merger and the PIPE Financing (see Note 3), and to a lesser extent, payments received in connection with collaboration and license agreements.
5
As of June 30, 2025 and December 31,
2024, the Company had an accumulated deficit of $
On April 2, 2025, the Company received written
notice (the “Notice”) from the Listing Qualifications Department staff (the “Staff”) of the Nasdaq Stock Market
(“Nasdaq”) notifying the Company that, based on the closing bid price of the Company’s common stock for the last 30
consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Stock
Market LLC. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $
Further, on April 10, 2025, the Company received
two letters from the Staff of Nasdaq. One letter (the “MVPHS Notice”) indicated that based upon Nasdaq’s review of the
Company’s Market Value of Publicly Held Shares (“MVPHS”) for the last 30 consecutive business days prior to the date
of the MVPHS Notice, the Company no longer meets the requirements of Nasdaq Listing Rule 5450(b)(2)(C), which requires listed securities
to maintain a minimum MVPHS of $
Under Nasdaq Listing Rule 5810(c)(3)(D), the Company
has a period of 180 calendar days (or until October 7, 2025) to regain compliance with the MVPHS Requirement. If at any time during this
compliance period the Company’s MVPHS closes at $
The Company also received a letter from the Staff
of Nasdaq (the “MVLS Deficiency Notice”) notifying the Company that from February 20, 2025, to April 9, 2025, the Company’s
Market Value of Listed Securities (“MVLS”) was below the minimum of $
On June 23, 2025, the Company received net proceeds
of $
On July 24, 2025, the Company issued the Advance
Notice to YA (see Note 17) in accordance with the terms of the SEPA, under which YA purchased from the Company
On July 25, 2025, the Company issued the
Advance Notice to YA in accordance with the terms of the SEPA, under which YA purchased from the Company
On August 5, 2025, the Company issued the Advance Notice to YA in accordance
with the terms of the SEPA, under which YA purchased from the Company
As of June 30, 2025, the Company had cash
of $
6
Accordingly, based on the considerations discussed above, management has concluded there is substantial doubt as to the Company’s ability to continue as a going concern within one year after the date the condensed consolidated financial statements are issued. The condensed consolidated financial statements do not include any adjustments with respect to the carrying amounts of assets and liabilities and their classification that might result from the outcome of this uncertainty.
| 2. | Summary of Significant Accounting Policies |
Basis of Presentation
The condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the applicable rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The accompanying condensed consolidated financial statements include all of the accounts of the Company and its subsidiaries, Abpro Corporation and AbMed Corporation (“AbMed”). All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Significant estimates in these condensed consolidated financial statements include stock-based compensation expense, the fair value of derivative instruments, the fair value of warrants, pre-clinical and clinical accrued expenses, the valuation and realizability of deferred tax assets, and the ability to continue as a going concern. On an ongoing basis, the Company evaluates its estimates, judgments, and methodologies. The Company bases its estimates on historical experience and on various other assumptions believed to be reasonable. Due to the inherent uncertainty involved in making estimates, actual results could differ materially from those estimates.
In March 2022, the Company received an invoice
from Mabwell (Shanghai) Bioscience Co., Ltd. (“Mabwell”) for approximately $
Unaudited Interim Condensed Consolidated Financial Statements
The accompanying interim condensed consolidated financial statements and the related footnote disclosures are unaudited. These unaudited interim financial statements have been prepared on the same basis as the audited financial statements, and in management’s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of June 30, 2025 and its results of operations for the three and six months ended June 30, 2025 and 2024, and cash flows for the six months ended June 30, 2025 and 2024. The results of operations for the three and six months ended June 30, 2025 are not necessarily indicative of the results to be expected for the year ended December 31, 2025 or any other period. The December 31, 2024 year-end condensed consolidated balance sheet was derived from audited annual financial statements but does not include all disclosures from the annual financial statements.
Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC. Accordingly, these condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2024 and the related notes included in the Company’s Annual Report on Form 10-K, filed with the SEC on April 15, 2025 (the “Annual Report”), which provides a more complete discussion of the Company’s accounting policies and certain other information. There have been no significant changes to the significant accounting policies disclosed in Note 2 of the audited consolidated financial statements as of and for the year ended December 31, 2024 included in the Company’s Annual Report.
7
Segment Reporting
ASC Topic No. 280, Segment Reporting (“ASC 280”), establishes standards for the way that public business enterprises report information about operating segments in their annual consolidated financial statements and requires that those enterprises report selected information about operating segments in interim financial reports. ASC 280 also establishes standards for related disclosures about products and services, geographic areas and major customers. The Company’s business segments are based on the organization structure used by the chief operating decision maker (“CODM”) for making operating and investment decisions and for assessing performance.
In accordance with ASC 280, the Company has determined
that it operates as a single reportable segment, which is the business of development of novel antibodies, primarily in the areas of immuno-oncology,
ophthalmology and infectious disease.
Non-controlling Interest
The Company holds an
Net Loss Per Share
The Company follows the two-class method to compute basic and diluted net loss per share attributable to common stockholders when shares meet the definition of participating securities. Series A, Series B, Series C, Series D, Series E and Series F preferred stock (see Note 13), which were outstanding prior to the Closing Date, met the definition of participating securities. The two-class method determines net income (loss) per common share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the earnings as if all income for the period had been distributed. During periods of loss, there is no allocation required under the two-class method due to there being no distributed earnings for the period coupled with the fact that the Company’s Series A, Series B, Series C, Series D, Series E and Series F preferred stock do not contain a contractual right to absorb losses. Thus, all undistributed losses were allocated entirely to the Company’s outstanding common stock for all periods presented.
Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period without consideration of potentially dilutive common stock. Diluted net loss per share attributable to common stockholders reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company unless the inclusion of such shares would be anti-dilutive. As the Company has incurred losses for the three and six months ended June 30, 2025 and 2024, basic and diluted net loss per share were the same for all periods presented.
8
The following table presents the potentially dilutive shares that were excluded from the computation of diluted net loss per share of common stock attributable to common stockholders, because their effect was anti-dilutive:
| June 30, | ||||||||
| 2025 | 2024 | |||||||
| Convertible Preferred Stock | ||||||||
| Warrants | ||||||||
| Stock options | ||||||||
| Convertible Notes | ||||||||
| Unvested restricted stock units | ||||||||
| Total | ||||||||
Recently Adopted Accounting Pronouncements
In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures,” that addresses requests for improved income tax disclosures from investors that use the financial statements to make capital allocation decisions. Public entities must adopt the new guidance for fiscal years beginning after December 15, 2024. The amendments in this ASU must be applied on a retrospective basis to all prior periods presented in the financial statements and early adoption is permitted. The Company adopted this standard on January 1, 2025 and determined that the adoption does not have a material impact on these unaudited condensed consolidated financial statements.
Recently Issued Accounting Pronouncements
On November 4, 2024, the FASB issued ASU 2024-03, Accounting Standards Update 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses to improve financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The amendments in this ASU do not change or remove current expense disclosure requirements; however, the amendments affect where such information appears in the notes to financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as the other disaggregation requirements in the amendments. This ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of this standard will have on its financial statements.
Management does not believe that any additional recently issued, but not yet effective, accounting standards, if currently adopted, would have a material impact on the Company’s financial statements.
| 3. | Merger |
On November 13, 2024, Merger Sub, a wholly-owned subsidiary of ACAB, merged with Legacy Abpro, with Legacy Abpro surviving as a wholly-owned subsidiary of ACAB. At the effective time of the Merger:
| ● | each outstanding share of Legacy Abpro common stock was converted into approximately |
9
| ● | each outstanding share of preferred stock of Legacy Abpro was converted into the aggregate number of shares of New Abpro’s common stock that would be issued upon conversion of the shares of Legacy Abpro preferred stock based on the applicable conversion ratio immediately prior to the effective time, multiplied by approximately |
| ● | each outstanding option or warrant to purchase Legacy Abpro common stock was converted into an option or warrant, as applicable, to purchase a number of shares of the New Abpro’s common stock equal to the number of shares of Legacy Abpro common stock subject to such option or warrant multiplied by approximately |
In addition, at the Closing Date,
Former holders of the Legacy Abpro common stock
and Legacy Abpro preferred stock are eligible to receive up to
At the Closing Date, the Company issued an aggregate
of
Pursuant to the terms of the Merger Agreement,
at the Closing Date, ACAB’s sponsor, Atlantic Coastal Management II LLC (the “Sponsor”) received
At the Closing, and in accordance with the Sponsor
Letter Agreement entered into on December 11, 2023, as amended, the Sponsor transferred
In addition, at the Closing, the Company issued
10
The number of shares of the Company’s common stock outstanding immediately following the consummation of the Merger was:
| Shares | ||||
| Common stock of ACAB, net of redemptions | ||||
| ACAB Founder Shares, less forfeitures and transfers | ||||
| New Abpro shares issued to PIPE investors | ||||
| New Abpro shares issued to service providers | ||||
| New Abpro shares issued in Merger to Legacy Abpro stockholders | ||||
| New Abpro shares transferred to investors | ||||
| New Abpro shares issued to settle the promissory note with executive | ||||
| Total shares of common stock outstanding immediately after Merger | ||||
The Merger was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, ACAB is treated as the acquired company for financial reporting purposes and Legacy Abpro is treated as the acquirer. This determination is primarily based on the fact that subsequent to the Merger, the Legacy Abpro stockholders hold a majority of the voting rights of the combined company, Legacy Abpro comprises all of the ongoing operations of the combined company, Legacy Abpro comprises a majority of the carryover governing body of the combined company, and Legacy Abpro’s senior management comprises all of the senior management of the combined company. Accordingly, for accounting purposes, the Merger was treated as the equivalent of Legacy Abpro issuing shares for the net assets of ACAB, accompanied by a recapitalization. The net assets of ACAB were stated at historical costs. No goodwill or other intangible assets were recorded. Operations prior to the Merger are those of Legacy Abpro.
The Company received $
In February 2025, the Company issued
11
| 4. | Property and Equipment |
The Company’s property and equipment include the following:
| June 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Furniture and fixtures | $ | $ | ||||||
| Lab equipment | ||||||||
| Computer hardware and software | ||||||||
| Leasehold improvements | ||||||||
| Equipment under finance leases | ||||||||
| Property and equipment | ||||||||
| Less: Accumulated depreciation | ( | ) | ( | ) | ||||
| Total | $ | $ | ||||||
Depreciation expense was $
| 5. | Accrued Expenses |
Accrued expenses consisted of the following:
| June 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Accrued salaries and wages | $ | $ | ||||||
| Accrued professional fees | ||||||||
| Accrued license fees | ||||||||
| Accrued interest | ||||||||
| BOD compensation | ||||||||
| Other accrued expenses | ||||||||
| Total accrued expenses | $ | $ | ||||||
| 6. | Fair Value Measurements |
The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2025 and December 31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company’s utilized to determine such fair value:
| June 30, | December 31, | |||||||||||
| Description | Level | 2025 | 2024 | |||||||||
| Assets: | ||||||||||||
| Forward purchase agreement asset (Note 10) | 3 | $ | $ | | ||||||||
| SEPA put rights asset (Note 12) | 3 | |||||||||||
| Liabilities: | ||||||||||||
| Embedded derivative liability (Note 12) | 3 | $ | $ | |||||||||
12
The Forward Purchase Agreement was fully settled
on January 28, 2025 for $
| December 31, | ||||
| 2024 | ||||
| Stock price | $ | | ||
| Risk-free interest rate | % | |||
| Expected term (in years) | ||||
| Expected volatility | % | |||
| Expected dividend yield | % | |||
The fair value of the SEPA put rights asset was
estimated as the sum of the fair values of the put rights under each assumed advance notice over the term of the SEPA. The number of shares
under each advance notice was based on the historical trading volumes of the Company’s stock taking into account the beneficial
ownership and daily volume limitations.
| June 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Stock price | $ | $ | ||||||
| Risk-free interest rate | % | |||||||
| Exercise price | $ | $ | ||||||
| Expected term (in years) | ||||||||
| Expected volatility | ||||||||
| Expected dividend yield | % | % | ||||||
| Number of shares under each advance notice | ||||||||
The fair value of the Embedded Derivative Liability
was estimated at $
As of December 31, 2024, the assumptions incorporated
into the valuation model included the stock price of $
The aggregate fair value of the Embedded Derivative
Liability associated with the conversions of the First Convertible Note of $
The changes in the fair value of Level 3 financial assets and liabilities for the six months ended June 30, 2025 are as follows:
| Forward Purchase Agreement asset | SEPA Put Rights Asset | Embedded Derivative Liability | ||||||||||
| Fair value as of January 1, 2025 | $ | $ | $ | |||||||||
| Initial measurement at the issuance date (Note 12) | ||||||||||||
| Settlement | ( | ) | ( | ) | ||||||||
| Change in fair value | ( | ) | ( | ) | ||||||||
| Fair value as of June 30, 2025 | $ | $ | $ | |||||||||
13
| 7. | License and Collaboration Agreements |
NJCTTQ Collaboration Agreement
In January 2019, the Company entered into a collaboration
agreement with Nanjing Chia Tai Tianquing Pharmaceutical Co., Ltd. (“NJCTTQ”) to research, develop and commercialize two anti-Claudin
18.2 lead antibodies (the “NJCTTQ agreement”). Under the NJCTTQ agreement, the Company granted a non-exclusive, non-sublicensable
research license and an exclusive, sublicensable license to NJCTTQ within the People’s Republic of China and Thailand (the “NJCTTQ
Territory”). The initial term of this agreement was
The Company was eligible to receive up to an aggregate
of $
The Company and NJCTTQ agreed to pay reciprocal
royalties, with each of them paying the other party low single-digit royalties, tiered based on net sales per calendar year in its territory.
The agreement remains unrenewed as of June 30, 2025 after the expiration of its initial term. However, notwithstanding the agreement’s
expiration, the low single-digit royalties and the $
ABP-201 Collaboration and License Agreement
In January 2020, the Company’s consolidated subsidiary, AbMed, entered into a collaboration and license agreement with ABI (the “ABP-201 Agreement”), pursuant to which the Company granted to ABI an exclusive, royalty-bearing, license under specified patent rights to make, use and sell certain of its proprietary ANG-2/VEGF-HIRK bispecific antibodies within the licensed territory comprising People’s Republic of China, Japan, South Korea, Southeast Asia, the Middle East and the Commonwealth of Independent States. Unless earlier terminated in accordance with its terms, the agreement remains in effect on a country-by-country basis until the expiration of the last royalty term in such country.
Under the ABP-201 agreement, ABI agreed to use
commercially reasonable efforts to reach certain development and commercialization milestones for such bispecific antibodies within specified
territories and timeframes. ABI is committed to pay the Company up to $
Celltrion Collaboration and License Agreement
In September 2022, the Company entered into an exclusive collaboration and license agreement with Celltrion (the “Original Celltrion Agreement”). The Company and Celltrion entered into an amendment to the agreement in October 2024 in connection with the execution of the Celltrion Subscription Agreement (the “Amended Celltrion Agreement”). The amendment is subject to termination by the Company or Celltrion if (i) the share purchase under the Celltrion Subscription Agreement is not completed, or (ii) the Celltrion Subscription Agreement is terminated pursuant to Section 7 of the Celltrion Subscription Agreement. Under the Amended Celltrion Agreement, the Company granted to Celltrion a worldwide exclusive license under specified patent rights to develop, make, have made, import, export, use, have used, sell and have sold certain of its proprietary ABP-102 bispecific antibodies. The license agreement also provides that the Company is to perform certain preclinical in vitro studies. The license agreement will remain in effect for so long as ABP-102 is being developed or commercialized anywhere in the world. Celltrion may terminate the license agreement at any time by providing six months prior written notice to the Company.
14
Celltrion is committed to pay the Company up to
$
The first milestone of $
During the three and six months ended June 30, 2025 and 2024, the Company recognized revenue in connection with this arrangement.
Milestone Payments. The Company is
entitled to development milestones under the Celltrion Agreement and certain regulatory milestone payments which are paid upon receipt
of regulatory approvals. Except for the first milestone of $
Profit Splits. As the license is deemed to be the predominant item to which profit splits relate, the Company will recognize revenue when the related sales or third-party collaborator income occur. No profit split revenue has been recognized from inception through June 30, 2025.
| 8. | Commitments under Research and Collaboration Agreements |
MedImmune License Agreement
In August 2016, the Company entered into a collaboration and license agreement with MedImmune Limited (“MedImmune”), pursuant to which the Company received from MedImmune an exclusive, worldwide, royalty-bearing, sublicensable (subject to certain conditions) license to certain intellectual property rights relating to the Company’s ABP-200 product candidates (the “MedImmune License Agreement”). The Company agreed to use commercially reasonable efforts to reach certain development and commercialization milestones for such bispecific antibodies within specified timeframes. Unless earlier terminated in accordance with its terms, the MedImmune License Agreement, as amended, remains in effect on a country-by-country basis until the expiration of the last royalty term in such country as to be determined by the launch of products based on the ABP-200 product candidates. The Company is no longer developing ABP-200.
Under the MedImmune License Agreement, the Company
agreed to pay milestone and royalty payments, including up to $
15
NCI License Agreement
In August 2017, the Company entered into a patent license agreement with the National Cancer Institute (the “NCI”), a division of the National Institutes of Health (the “NIH”), pursuant to which the Company received an exclusive, worldwide license to make, use, sell, offer to sell and import products covered by the licensed patents in the field of using certain monoclonal antibodies as monospecific or bispecific antibodies for the treatment of liver cancer (the “NCI License Agreement”). The license agreement was amended in May 2020 and October 2023 and the field of use was narrowed to the development and commercialization of a bispecific antibody for the treatment of GPC-3 expressing liver cancer using a particular moiety for targeting GPC3 and the timeline for development and commercialization was extended. Unless earlier terminated, the Company’s agreement with NCI will expire upon expiration of all licensed patent rights. The Company may also terminate the agreement as to any licenses in any country or territory upon 60 days written notice.
Pursuant to the NCI agreement and amendments,
the Company agreed to pay low single-digit royalties based on net sales of licensed products as well as milestone payments of up to $
The Company also has to pay the guaranteed annual
minimum royalties of $
The Company also agreed to reimburse patent costs for all documented out of pocket associated with the preparation, filing, prosecution and maintenance of patent rights. During the three and six months ended June 30, 2025 and 2024, the Company did not incur any expenses related to the patent costs reimbursements.
Mabwell License Agreement
In October 2020, the Company entered into an exclusive collaboration and license agreement with Mabwell (the “Mabwell License Agreement”). The agreement was amended in November 2020. Under the Mabwell license agreement, the Company received a non-exclusive, royalty-free research purpose license as well as an exclusive commercial license within certain territories, as defined in the agreement, to Mabwell’s series of anti-SARS-CoV-2 monoclonal antibodies. Under the agreement, the Company is responsible for conducting at its sole expense, research and preclinical, clinical and other developments of any licensed products and bears all development costs and expenses related to obtaining or maintenance of marketing authorizations of licensed products in its territories. Mabwell is obligated, at the Company’s request, to supply the Licensed Antibodies to the Company for clinical trial purpose at costs plus margin as defined in the agreement. The parties agreed to undertake certain joint clinical research and development activities with a portion of the costs contributed by Mabwell. Unless earlier terminated, the Mabwell License Agreement will expire on the occurrence of the last to expire royalty term, which is the later of a) the expiration of the last to expire valid claim of the patent rights and b) ten years from the first commercial sale of such Licensed Product, and determined on jurisdiction-by-jurisdiction basis. Either party may terminate the agreement in the event of any uncured material breach by the other party.
The agreement provides for development milestones
of up to $
16
During the three and six months ended June 30, 2025 and 2024, development activities under the Mabwell collaboration agreement were immaterial to the condensed consolidated financial statements. No milestones have been reached and no products were sold under the Mabwell License Agreement through June 30, 2025.
In March 2025, the Company received a draft of
a termination agreement from Mabwell which outlines Mabwell’s claim for the total payment of $
MSK License Agreement
In March 2017, the Company entered into an exclusive license agreement with Memorial Sloan Kettering Cancer Center (the “MSK License Agreement”), pursuant to which the Company received an exclusive, royalty-bearing, worldwide license under specified patent rights to make, use and sell certain of MSK’s proprietary Her2-huOKT3 bispecific antibodies. The agreement was amended on March 31, 2017, on March 31, 2018, and January 1, 2020. Unless earlier terminated in accordance with its terms, the agreement was to remain in effect on a country-by-country basis until the expiration of the last royalty term in such country as to be determined by the launch of products based on MSK antibodies. On September 19, 2023, MSK License Agreement was terminated by MSK due to the Company’s failure to make the payments for the patent costs reimbursements discussed below.
Under the MSK License Agreement, as amended, the
Company agreed to use commercially reasonable efforts to reach certain development and commercialization milestones for such bispecific
antibodies within specified territories and timeframes. The Company was committed to pay MSK up to $
The Company also agreed to reimburse patent costs
for all documented out of pocket costs associated with the preparation, filing, prosecution and maintenance of patent rights in the license
territory. During the three and six months ended June 30, 2025 and 2024, the Company did not incur any patent reimbursement costs. As
of both June 30, 2025 and December 31, 2024, the liabilities for the patent costs reimbursements were $
As of both June 30, 2025 and December 31, 2024,
the accrued liabilities for the unpaid interest on the outstanding minimum royalty and milestone payments due to MSK were $
VAZYME License agreement
In April 2021, the Company entered into a License Agreement with VAZYME Biotech Co., Ltd (“VAZYME”) (the “VAZYME License Agreement”), pursuant to which the Company was granted an exclusive, perpetual, royalty-bearing, worldwide license under specified patent rights to research, develop and commercialize VAZYME proprietary anti-SARS-CoV-2 monoclonal antibodies. Unless earlier terminated in accordance with its terms, the agreement remains in effect on a country-by-country basis until the expiration of the last royalty term in such country.
17
Under the VAZYME License Agreement, the Company
agreed to use commercially reasonable efforts to reach certain research and development, and commercialization milestones for such antibodies.
The Company also agreed to pay $
In December 2021, the Company entered into a Cooperation Agreement with Chengdu Bio-Innovate Pharmaceutical Technology Co., Ltd (“Bio-Innovate”) and a three-way sharing agreement with VAZYME and Bio-Innovate (“the Company”, “VAZYME” and “Bio-Innovate”, collectively “all parties”), pursuant to which the Company entrusted Bio-Innovate to perform certain preclinical testing and all parties agreed that VAZYME will ship the agreed antibodies to Bio-Innovate rather than the Company to fulfill the requirements under the VAZYME License Agreement.
For the three and six months ended June 30, 2025
and 2024, the Company did not incur any expenses related to the VAZYME License Agreement. As of both June 30, 2025 and December 31, 2024,
the accrued liabilities under this agreement were $
| 9. | Commitments and Contingencies |
Litigation and other matters
The Company, from time to time, is subject to legal proceedings and claims that arise in the ordinary course of business. Resolution of any such matter could have a material adverse effect on the results of operations and financial condition. The Company considers all claims on a periodic basis and based on known facts assesses whether potential losses are considered reasonably possible, probable and estimable. Based upon this assessment, the Company then evaluates disclosure requirements and whether to accrue for such claims in its consolidated financial statements.
The Company records a provision for contingent liability when it is both probable that a loss has been incurred and the amount of the loss can be reasonably estimated.
On September 12, 2023, a contract research organization
(“CRO”) vendor filed a lawsuit against the Company based on the Company’s failure to make certain installments pursuant
to a settlement agreement entered into with this vendor on January 23, 2023. Under the settlement agreement, the Company agreed to pay
a total of $
In addition to the lawsuit from a CRO vendor above,
the Company accrued $
In June 2023, the Company received a notice of
breach from MSK followed by a notice of termination in September 2023, pursuant to which MSK demanded payments totaling $
The MedImmune License Agreement (see Note 8) provides for a research plan with target dates for an IND application (July 2021) and Phase II commencement (December 2022). These target dates were not met, which gives MedImmune (now AstraZeneca) a termination right. The Company does not expect a material impact on our business if MedImmune/AstraZeneca terminates this agreement. This license was originally entered into in connection with the development of ABP-200, which the Company is no longer developing. The Company believes that it does not need the intellectual property licensed under that agreement for the development and eventual commercialization of ABP-201 or any of its other programs.
18
On June 17, 2025, the Company received a complaint
from a former director of Legacy Abpro asserting that the Company owes the former director a total of $
Non-Redemption Agreement
On November 5, 2024, Legacy Abpro and ACAB entered
into a non-redemption agreement (the “Non-Redemption Agreement”), with Sandia Investment Management LP
on behalf of certain funds, investors, entities or accounts for which it or its affiliates acts as manager, sponsor or advisor (the “NRA
Investors”). Pursuant to such Non-Redemption Agreement, each NRA Investor agreed to rescind or reverse any previously
submitted redemption demand of the common stock of the Company held or to be acquired by such NRA Investor (the “NRA Investor Shares”)
up to
At the Closing Date, the NRA Investors reversed redemption
demands with respect to
Excise Tax Liability
At the Closing Date, the Company assumed the excise
tax liability of $
On August 16, 2022, the Inflation Reduction Act
of 2022 (the “IR Act”) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal
During the second quarter of 2024, the Treasury and Internal Revenue Service (“IRS”) issued final regulations with respect to the timing and payment of the excise tax. Pursuant to those regulations, the Company would need to file a return and remit payment for any liability incurred during the period from January 1, 2023 to December 31, 2023 on or before October 31, 2024. The Company has filed the excise tax return and has engaged with the IRS in determining a payment plan for the balance.
The Company is unable to pay its obligation in
full, and, as such, it is subject to additional interest and penalties which are currently estimated at
In March 2025, the Company received the letter
from the IRS, requesting to set up a meeting with the Company to discuss the unsettled tax matters of ACAB and referencing $
19
| 10. | Forward Purchase Agreement |
On November 7, 2024, ACAB and Legacy Abpro entered
into a Confirmation of an OTC Equity Prepaid Forward Transaction (the “Forward Purchase Agreement” or “Transaction”)
with YA (the “Seller”) to which a maximum of up to
The number of Recycled Shares subject to the Forward Purchase Agreement was also subject to reduction following a termination of the Forward Purchase Agreement with respect to such shares as described under “Optional Early Termination” below. The contract was to settle based on the settlement terms discussed below.
Optional Early Termination
From time to time and on any date following the Closing Date (any such date, an “OET Date”) and subject to the terms and conditions in the Forward Purchase Agreement (“Optional Early Termination”), the Seller may, in its absolute discretion, terminate the Transaction in whole or in part by providing written notice to the Company (the “OET Notice”), by no later than the next payment date following the OET Date, (which will specify the quantity by which the Number of Shares will be reduced (such quantity, the “Terminated Shares”)). The effect of an OET Notice would be to reduce the Number of Shares by the number of Terminated Shares specified in such OET Notice with effect as of the related OET Date. As of each OET Date, the Company would be entitled to an amount from the Seller, and the Seller would pay to the Company an amount, equal to the product of (x) the number of Terminated Shares and (y) the reset price in respect of such OET Date.
The reset price (the “Reset Price”)
was initially $
Settlement
On the Cash Settlement Payment Date, which is
the tenth local business day immediately following the Valuation Date (defined below), the Seller had to remit to the Company a cash amount
(the “Settlement Amount”) equal to (i) the Number of Shares as of the Valuation Date, multiplied by (ii) the difference of
(a) the volume weighted daily VWAP price over the Valuation Period, less (b) $
On January 28, 2025, YA elected to effect an Optional
Early Termination with respect to all
20
The Forward Purchase Agreement was accounted for
at fair value as an asset in accordance with the guidance in ASC Topic No. 815 Derivatives and Hedging (“ASC 815”), with subsequent
changes in the fair value recorded in profits and losses. The fair value of the Forward Purchase Agreement asset was $
| 11. | Notes Payable |
Note Payable
During the six months ended June 30, 2025, the
Company entered into an insurance premium financing agreement and borrowed a total principal amount of $
Notes Payable – Related Parties
Promissory Note with ABI
On October 18, 2023, the Company entered into
a promissory note agreement with ABI, a significant investor in the Company, to receive up to $
On October 7, 2024, the Company entered into an
additional promissory note with ABI (“the 2024 ABI Note”) to receive up to $
As of both June 30, 2025 and December 31, 2024,
the outstanding principal balances under the promissory notes with ABI was $
Promissory Notes with Executive and Director
On December 29, 2023, the Company issued promissory
notes to one of its executives and one of its former directors, in the principal amount of $
21
On April 18, 2024, the Company entered into a separate
promissory note agreement with the same executive to receive, as amended, up to $
Pursuant to the terms of the promissory note from
April 18, 2024, the Company agreed to cause to be issued to the executive a number of New Abpro stock options or warrants in an amount
equal to the outstanding principal amount of such promissory note, subject to required approval by the New Abpro Board of Directors (“BOD”)
and Compensation Committee and registration of such securities on Form S-8. On February 7, 2025, the Company issued
Promissory Note with ACAB Executive
On August 16, 2024, an executive at ACAB agreed
to loan Legacy Abpro $
On November 21, 2024, the ACAB Executive Note
was amended to clarify that it should have been between Legacy Abpro as borrower and ACAB as lender. Pursuant to the Severance Agreement
(see Note 16), the liability to the ACAB executive was cancelled. According to the terms of the amended note, Legacy Abpro was to repay
the principal amount of $
| 12. | Standby Equity Purchase Agreement |
Convertible Notes
On October 30, 2024, Legacy Abpro and ACAB entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, Ltd. (“YA”).
Subject to the satisfaction of the conditions
set forth in the SEPA, YA committed to advance to the Company the aggregate principal amount of up to $
22
On November 14, 2024 (the “First Convertible
Note Issuance Date”), pursuant to the SEPA, the Company entered into a Convertible Promissory Note (the “First Convertible
Note”) with YA for $
On June 23, 2025 (the “Second Convertible
Note Issuance Date”), pursuant to the SEPA, the Company entered into a Convertible Promissory Note (the “Second Convertible
Note” and together with the First Convertible Note, the “Convertible Notes”) with YA for $
The Convertible Notes have a maturity date of
The Convertible Notes are convertible at the option
of the holder at any time after the issuance dates based on the conversion price determined as the lower of (i) $
On April 20, 2025, the Company entered into an
amendment to SEPA with YA, pursuant to which, the definition of the conversion price was amended to state that the Fixed Price should
be adjusted (downwards only) to equal the VWAP of the Common Shares over the three (3) Trading Days immediately preceding the 20th Trading
Day following the Issuance Date if such price is lower than the initial Fixed Price. As a result, at the amendment date, the Fixed Price
was reset down to $
The Convertible Notes are redeemable at the option
of the Company if the volume-weighted-average price (“VWAP”) of the Company’s Common Stock is less than $
Under the terms of the Convertible Notes, the
Amortization Event occurs if i) the daily VWAP is less than the Floor Price for
23
It was determined, in accordance with ASC 815,
that the Conversion Feature is required to be bifurcated due to the adjustments to the settlement amount of this embedded feature that
are not inputs to the fair value measurement of a fixed-for-fixed forward or option on equity shares, and should be recorded as a liability
(the “Embedded Derivative Liability”) at fair value with a corresponding amount recorded as a discount on the Convertible
Notes. The Embedded Derivative Liability is marked to market at each reporting period end with any changes recorded in other income or
expense. The fair value of the Embedded Derivative Liability associated with the First Convertible Note was estimated at $
During the three months ended June 30, 2025, the First
Convertible Note was fully converted at the option of YA into an aggregate of
The total discount resulting from the Convertible
Note Discount and the bifurcation of the Embedded Derivative Liability at the issuance dates are amortized over the terms of the Convertible
Notes through non-cash interest expense using the effective interest method. The non-cash interest expense related to the discount amortization
was $
SEPA Put Rights
Under the terms of the SEPA, starting at the Closing
Date, the Company has the right, but not the obligation (“SEPA Put Rights”), to issue shares of its common stock to YA (“Advance
Shares”, and such issuance and sale, an “Advance”) and YA shall subscribe for and purchase from the Company such Advance
Shares, through written notice by the Company to YA (“Advance Notice”), provided (i) no balance is outstanding under
a Convertible Note, or (ii) if there is a balance outstanding under a Convertible Note, an Amortization Event (as defined above),
has occurred in accordance with and subject to the terms of the SEPA. The SEPA contemplates purchase by YA of up to $
For as long as there is an outstanding balance under a Convertible Note, YA has the right, but not the obligation, by delivery to the Company of Investor Notices (as defined in the SEPA), to cause an Advance Notice to be deemed delivered by YA, which triggers the issuance and sale of Advance Shares to YA, subject to terms and conditions as specified in the SEPA.
24
The purchase price for the Advance Shares shall
be the price per Advance Share obtained by multiplying the Company’s stock price (i) by
The Company accounted for the SEPA Put Rights
as an asset at fair value in accordance with the guidance in ASC 815, due to the adjustments to the settlement amount of this derivative
instrument that are not inputs to the fair value measurement of a fixed-for-fixed forward or option on equity shares. The fair value of
the SEPA Put Rights was $
As consideration for YA’s commitment to
purchase shares of common stock, upon execution of the SEPA, the Company engaged to remit YA the commitment fee of $
| 13. | Stockholders’ Equity |
Convertible Preferred Stock
As of December 31, 2023, and immediately prior
to the Closing Date, Legacy Abpro’s amended and restated articles of incorporation authorized the issuance of up to
In connection with the Merger, all previously
issued and outstanding Convertible Preferred Stock was converted into the aggregate number of shares of New Abpro’s common stock
that would be issued upon conversion of the shares of Legacy Abpro preferred stock based on the applicable conversion ratio immediately
prior to the effective time, multiplied by the exchange ratio of approximately
Common and Preferred Stock
In connection with the Closing, the Company’s
articles of incorporation were amended to designate two classes of stock; preferred and common stock. The articles of incorporation of
New Abpro authorize
The Company’s Amended and Restated Certificate
of Incorporation provides the Company’s board of directors with the authority to issue up to
25
Warrants
As of both June 30, 2025 and December 31, 2024,
there were
The Company will not be obligated to deliver any common stock pursuant to the exercise of a Public Warrant and will have no obligation to settle such Public Warrant exercise unless a registration statement under the Securities Act covering the issuance of the common stock issuable upon exercise of the Public Warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations with respect to registration. No warrant will be exercisable, and the Company will not be obligated to issue shares of common stock upon exercise of a warrant unless common stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants.
The Company may redeem the Public Warrants:
| ● | in whole and not in part; |
| ● | at
a price of $ |
| ● | upon not less than 30 days’ prior written notice of redemption given after the warrants become exercisable to each warrant holder; and |
| ● | if,
and only if, the reported last sale price of the Series A common stock equals or exceeds $ |
If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws.
If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. The exercise price and number of shares of common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization, merger or consolidation. However, except as described below, the warrants will not be adjusted for issuance of common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants.
As of both June 30, 2025 and December 31, 2024,
there were
In addition, if (x) the Company were to issue
additional shares of common stock or equity-linked securities, for capital raising purposes in connection with the closing of a Merger
at an issue price or effective issue price of less than $
26
In November 2024, the “Down Round Feature”
was triggered and the exercise price of the Public and Private Warrants was adjusted down to $
The Company valued the deemed dividend as the
difference between the fair value of the warrants before and after the exercise price adjustment. The warrants were valued using the Black-Scholes
option pricing model immediately before and after the modification using the following assumptions: (a) fair value of common stock of
$
The
On February 7, 2025, the Company issued
The following presents information about warrants to purchase common stock outstanding as of June 30, 2025:
| Weighted- | Average | |||||||||
| Average | Remaining | |||||||||
| Shares | Exercise Price | Contractual Life | ||||||||
| Warrants | $ | |||||||||
No warrants were exercised during the six months ended June 30, 2025.
| 14. | Share-Based Compensation |
2024 Equity Incentive Plan
The Company’s 2024 Equity Incentive Plan
(the “2024 Plan”) became effective at the Closing Date. As of June 30, 2025,
Under the 2024 Plan, the Company can grant non-statutory stock options, or NSOs, incentive stock options, or ISOs, stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, performance awards and other forms of awards to eligible employees and nonemployees. Through June 30, 2025, the Company has not granted any awards under the 2024 Plan.
2014 Stock Incentive Plan
The 2014 Stock Incentive Plan (the “2014
Plan”) of Legacy Abpro was expired as of the Closing Date, in accordance with its original terms. As a result of the expiration,
no further awards may be granted under the 2014 Plan. All awards previously granted and outstanding as of the effective date of the Merger,
which totaled
27
Stock Options
The summary of the Company’s stock option activity is as follows:
| Number of Stock Options | Weighted- Average Exercise Price | Weighted- Average Remaining Contractual Life | ||||||||||
| Outstanding at December 31, 2024 | $ | | ||||||||||
| Granted | ||||||||||||
| Exercised | ||||||||||||
| Forfeited/Expired/Cancelled | ( | ) | $ | |||||||||
| Outstanding at June 30, 2025 | $ | |||||||||||
| Exercisable at June 30, 2025 | $ | |||||||||||
Restricted Stock Units
The Company granted restricted stock units (“RSUs”) to various employees and directors under the 2014 Plan. These RSUs cliff vest on the first anniversary of the grant date. The fair value of the RSUs is determined based upon the fair value of the underlying common stock as of the grant date.
The summary of the Company’s restricted stock unit activity is as follows:
| Number | Weighted-Average | Weighted-Average | ||||||||||
| of | Grant Date | Remaining | ||||||||||
| Shares | Fair Value | Vesting Period | ||||||||||
| Outstanding at December 31, 2024 | $ | | | |||||||||
| Granted | ||||||||||||
| Vested | ( | ) | ||||||||||
| Forfeited | ||||||||||||
| Outstanding at June 30, 2025 | $ | |||||||||||
During the six months ended June 30, 2025,
On October 22, 2024, the Company’s board
of directors authorized the issuance of
Stock-Based Compensation Expense
The summary of the recorded stock-based compensation expense is as follows:
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Research and development | $ | $ | $ | $ | ||||||||||||
| General and administrative | ||||||||||||||||
| Total stock-based compensation | $ | $ | $ | $ | ||||||||||||
As of June 30, 2025, there was approximately $
28
| 15. | Employee Benefit Plan |
The Company has a 401(k) retirement plan available
to all eligible employees. During the three and six months ended June 30, 2025, the Company made $
| 16. | Related Parties |
The Company has certain accrued unpaid interest and promissory notes outstanding with ABI, a current director, and a former director. See Note 11.
On January 15, 2020, the Company entered into
an agreement for various consulting services, as defined in the agreement, with a member of the Company’s Board of Directors. On
January 1, 2023, the Company entered into a new consulting agreement with the same director, which superseded the agreement dated in January
2020. The agreement was terminated during the year ended December 31, 2024. During the three and six months ended June 30, 2025, the Company
incurred $
On April 18, 2024, the Company entered into a
promissory note agreement with an executive to receive, as amended, for up to $
On April 18, 2024, the Company entered into an
agreement with an executive to defer payment of compensation from April 18, 2024 until the earlier of (i) the closing of the Merger and
(ii) November 20, 2024. The executive’s deferred wages were repaid in the amount of $
On November 21, 2024, the Company entered into
a severance agreement with an executive (the “Severance Agreement”). Pursuant to the terms of the Severance Agreement, the
Company made a severance payment of $
On December 24, 2024, the Company made a payment
of $
On July 25, 2025, the Company signed the CEO Consulting Agreement (see Note 17) with BioCelsus International Inc., an entity wholly owned by the CEO.
| 17. | Subsequent Events |
In July 2025, the Company entered into an arrangement with the landlord under which the Company agreed to vacate the leased office space in Woburn, MA by July 31, 2025. The Company paid all amounts due under the original lease agreement, which was set to expire in September 30, 2025 and no additional amounts are owed to the landlord as of the date of this agreement.
On July 24, 2025, the Company issued the Advance Notice
to YA in accordance with the terms of the SEPA, under which YA purchased from the Company
On July 25, 2025, the Company issued the
Advance Notice to YA in accordance with the terms of the SEPA, under which YA purchased from the Company
On August 5, 2025, the Company issued the
Advance Notice to YA in accordance with the terms of the SEPA, under which YA purchased from the Company
In July 2025, the Second Convertible note was
fully converted at the option of YA into an aggregate of
On July 25, 2025, in connection with a consulting
agreement executed between the Company and the Chief Executive Officer (“CEO”)(the “CEO Consulting Agreement”),
the Company issued
In August 2025, the Company entered into a membership
agreement for its office space in Burlington, MA. The agreement term begins on September 1, 2025 and ends on February 28, 2026, and provides
for monthly membership fees of approximately $
29
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q (“Quarterly Report”) and with our audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (the “SEC”) on April 15, 2025 (the “Annual Report”). In addition, you should read the “Risk Factors” and “Information Regarding Forward-Looking Statements” sections of this Quarterly Report and our Annual Report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.
Unless otherwise indicated or the context otherwise requires, references in this section to “New Abpro,” “we,” “us,” “our,” “the Company,” and other similar terms refer to Abpro Holdings, Inc. and its subsidiaries.
Overview
Abpro Holdings, Inc. and its subsidiaries (the “Company”) is a biotechnology company headquartered in Burlington, Massachusetts, dedicated to developing next-generation antibody therapeutics to improve the lives of patients with severe and life-threatening diseases. The Company is focused on the development of novel antibodies using its proprietary discovery and engineering platforms, primarily in the areas of immuno-oncology, ophthalmology and infectious disease.
By leveraging our proprietary DiversImmune® and MultiMabTM antibody discovery and engineering platforms, we are developing a pipeline of antibodies, both independently and through collaborations with global pharmaceutical and research institutions.
Our two lead product candidates, ABP-102 and ABP-201, feature our next generation tetravalent antibody format, or TetraBi antibody format, which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting human epidermal growth factor receptor 2, or HER2, and cluster of differentiation 3, or CD3, T-cell co-receptor. We plan initially to develop ABP-102 for difficult to treat HER2+ solid tumors, focusing on orphan indications. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting vascular endothelial growth factor, or VEGF, and angiopoietin-2, or ANG-2. We plan to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD). We intend to follow these two lead product candidates with a broad pipeline of CD3-targeting T-cell engagers based on the differentiated format of ABP-102. We expect to initiate clinical trials for ABP-102 in the first half of 2026. The initiation of clinical trials for ABP-201 may depend on future funding availability.
Merger
On November 13, 2024 (the “Closing Date”), Atlantic Costal Acquisition Corp. II (“ACAB”) consummated a merger (the “Merger”) pursuant to the terms of the Merger Agreement, dated as of December 11, 2023 (the “Merger Agreement”) by and among Abpro Corporation (“Legacy Abpro”), ACAB, and Abpro Merger Sub Corp., a Delaware corporation (“Merger Sub”) and wholly owned subsidiary of ACAB prior to the Closing. Pursuant to the Merger Agreement, on the Closing Date, (i) ACAB changed its name to “Abpro Holdings, Inc.” (“New Abpro”), and (ii) Merger Sub merged with and into Legacy Abpro, with Legacy Abpro as the surviving company in the Merger (such transactions, the “Merger,” and, collectively with the other transactions described in the Merger Agreement, the “Reverse Recapitalization”). After giving effect to the Merger, Legacy Abpro became a wholly owned subsidiary of the Company. Shares of the New Abpro commenced trading on the Nasdaq Global Market on November 14, 2024.
In addition, certain investors purchased an aggregate of 3,367,401 shares of Common Stock in a private placement that closed concurrently with the Closing for an aggregate purchase price of $11.2 million (the “PIPE Financing”). Unless otherwise noted, the Company has retroactively adjusted all common and preferred share and related price information to give effect to the Exchange Ratio as set forth in the Merger Agreement.
30
Impact of Macroeconomic Events
The Company is subject to risks and uncertainties arising from changes to the macroeconomic environment and geopolitical events. U.S. and global financial markets have experienced volatility and disruption due to macroeconomic and geopolitical events such as the implementation of tariffs, inflation, the risk of a recession and ongoing conflicts in other countries. In addition, if equity and credit markets deteriorate, it may make any future debt or equity financing more difficult to obtain on favorable terms, and potentially more dilutive to existing stockholders. The Company cannot predict at this time to what extent it and its collaborators, employees, suppliers, contract manufacturers and/or vendors could potentially be negatively impacted by these events.
Results of Operations
Comparison of the Three Months Ended June 30, 2025 and 2024
The following is a comparative discussion of our results of operations for the three months ended June 30, 2025 and 2024 (in thousands):
| Three Months Ended June 30, | ||||||||||||||||
| 2025 | 2024 | Change | % | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 313 | $ | 827 | $ | (514 | ) | -62 | % | |||||||
| General and administrative | 1,948 | 1,513 | 435 | 29 | % | |||||||||||
| Total operating expenses | 2,261 | 2,340 | (79 | ) | -3 | % | ||||||||||
| Loss from operations | (2,261 | ) | (2,340 | ) | 79 | -3 | % | |||||||||
| Other expense, net | (723 | ) | (100 | ) | (623 | ) | 623 | % | ||||||||
| Net loss | $ | (2,984 | ) | $ | (2,440 | ) | $ | (544 | ) | -22 | % | |||||
Revenue
We did not generate revenue during either of the three month periods ended June 30, 2025 and 2024. Our ability to generate product revenue in the future will depend almost entirely on our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize a drug candidate, or enter into collaborations that provide for payments to us.
Operating Expenses
Research and Development Expenses
Research and development expenses consist primarily of salaries, payroll taxes, employee benefits and stock-based compensation for those individuals involved in research and development efforts, as well as consulting expenses, third-party research and development expenses, laboratory supplies and clinical materials.
The following table summarizes our research and development expenses by product candidate and program for the three months ended June 30, 2025 and 2024 (in thousands):
| For the Three Months Ended June 30, | ||||||||
| Research and development expenses | 2025 | 2024 | ||||||
| ABP-110 | $ | 11 | $ | 25 | ||||
| ABP-102 | 44 | 171 | ||||||
| ABP-150 | 5 | 9 | ||||||
| ABP-201 | - | 8 | ||||||
| ABP-100 | - | - | ||||||
| SARS-Co V-2 neutralizing antibody program | - | 20 | ||||||
| Unallocated research and development expenses | 253 | 594 | ||||||
| Total | $ | 313 | $ | 827 | ||||
31
Unallocated research and development expenses include engineering platform-related expenses that are not allocable to a specific product candidate or program, as well as stock-based compensation, other employee-related expenses that are not related to a specific product candidate or program, and facilities and depreciation expenses.
Research and development expenses decreased by $0.5 million for the three months ended June 30, 2025, as compared to the three months ended June 30, 2024, primarily due to the majority of the personnel being on furlough since October 2024. The overall decrease in expenses was a result of the decrease in research and development activities while raising additional capital necessary to restart our research and development programs.
General and Administrative Expenses
General and administrative expenses consist primarily of compensation and benefits to our personnel not involved in research and development efforts, costs related to our directors, and senior advisors; professional service fees, including accounting and legal services and other consulting services. General and administrative expenses increased by $0.4 million for the three months ended June 30, 2025, as compared to the three months ended June 30, 2024, primarily due to an increase of approximately $1.0 million in costs of operating as a public company, including legal, accounting, and insurance expenses, partially offset by a decrease in payroll and related expenses of approximately $0.6 million as a result of the reduction in employee headcount.
Other Expense, Net
The net other expense increased by $0.6 million for the three months ended June 30, 2025, as compared to the three months ended June 30, 2024. This change is primarily due to the loss of approximately $0.6 million on the change in the fair value of the embedded derivative liabilities during the three months ended June 30, 2025, the increase in interest expense of approximately $0.1 million primarily related to the convertible notes entered into in the fourth quarter of 2024, and the loss on the settlement of the convertible notes of approximately $0.1 million recognized during the three months ended June 30, 2025, offset by other income of $0.2 million during the three months ended June 30, 2025 related to extinguishment of accrued liabilities.
Comparison of Six Months Ended June 30, 2025 and 2024
The following is a comparative discussion of our results of operations for the six months ended June 30, 2025 and 2024 (in thousands):
| For the Six Months Ended June 30, | ||||||||||||||||
| 2025 | 2024 | Change | % | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 638 | $ | 1,827 | $ | (1,189 | ) | -65 | % | |||||||
| General and administrative | 4,581 | 3,392 | 1,189 | 35 | % | |||||||||||
| Total operating expenses | 5,219 | 5,219 | - | 0 | % | |||||||||||
| Loss from operations | (5,219 | ) | (5,219 | ) | - | 0 | % | |||||||||
| Other (expense) income, net | (1,652 | ) | 3,415 | (5,067 | ) | -148 | % | |||||||||
| Net loss | $ | (6,871 | ) | $ | (1,804 | ) | $ | (5,067 | ) | -281 | % | |||||
Revenue
We did not generate revenue during either of the six month periods ended June 30, 2025 and 2024. Our ability to generate product revenue in the future will depend almost entirely on our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize a drug candidate, or enter into collaborations that provide for payments to us.
32
Operating Expenses
Research and Development Expenses
The following table summarizes our research and development expenses by product candidate and program for the six months ended June 30, 2025 and 2024 (in thousands):
| For the Six Months Ended June 30, | ||||||||
| Research and development expenses | 2025 | 2024 | ||||||
| ABP-110 | $ | 21 | $ | 61 | ||||
| ABP-102 | 134 | 446 | ||||||
| ABP-150 | 10 | 14 | ||||||
| ABP-201 | 33 | 15 | ||||||
| ABP-100 | - | - | ||||||
| SARS-Co V-2 neutralizing antibody program | - | 20 | ||||||
| Unallocated research and development expenses | 440 | 1,271 | ||||||
| Total | $ | 638 | $ | 1,827 | ||||
Research and development expenses decreased by $1.2 million for the six months ended June 30, 2025, as compared to the six months ended June 30, 2024, primarily due to the majority of the personnel being on furlough since October 2024. The overall decrease in expenses was a result of the decrease in research and development activities while raising additional capital necessary to restart our research and development programs.
General and Administrative Expenses
General and administrative expenses increased by $1.2 million for the six months ended June 30, 2025, as compared to the six months ended June 30, 2024, primarily due to an increase of approximately $2.0 million in costs of operating as a public company, including legal, accounting, and insurance expenses, partially offset by a decrease in payroll and related expenses of approximately $0.8 million as a result of the reduction in employee headcount.
Other Income (Expense), Net
The other income (expense), net decreased by $5.3 million from $3.4 million of other income for the six months ended June 30, 2024 down to $1.9 million of other expense for the six months ended June 30, 2025. During the six months ended June 30, 2024 the Company recognized other income of approximately $3.5 million related to the reversal of the liability to one of the Company’s research and development providers, as this provider informed the Company they were not pursuing collection on this liability. The remaining change is due to the increase in interest expense of approximately $0.9 million, primarily related to the fair value of the warrants issued under the promissory note with an executive, the loss of approximately $0.6 million for the change in fair value of embedded derivative liabilities, and the loss of approximately $0.2 million for the change in fair value of the SEPA Put Rights asset during the six months ended June 30, 2025, offset by other income of $0.2 million during the three months ended June 30, 2025 related to extinguishment of accrued liabilities.
Liquidity, Capital Resources and Going Concern
To date, we have financed our operations primarily through the sale of equity securities and convertible debt, proceeds from the Merger and related PIPE Financing, borrowings under loan facilities and, to a lesser extent, through payments received in connection with collaboration and license agreements. Since our inception, we incurred significant recurring losses, including the net loss of $6.9 million and $1.8 million for the six months ended June 30, 2025, and 2024, respectively. As of June 30, 2025, we had an accumulated deficit of $123.0 million. We expect to incur operating losses in the foreseeable future.
33
On April 2, 2025, the Company received written notice (the “Notice”) from the Listing Qualifications Department staff (the “Staff”) of Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Stock Market LLC. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”), and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement exists if the deficiency continues for a period of 30 consecutive business days. Pursuant to the Nasdaq Listing Rules, the Company has been provided an initial compliance period of 180 calendar days to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of 10 consecutive business days prior to September 29, 2025.
Further, on April 10, 2025, the Company received two letters from the listing qualifications department staff (the “Staff”) of The Nasdaq. One letter (the “MVPHS Notice”) indicated that based upon Nasdaq’s review of the Company’s Market Value of Publicly Held Shares (“MVPHS”) for the last 30 consecutive business days prior to the date of the MVPHS Notice, the Company no longer meets the requirements of Nasdaq Listing Rule 5450(b)(2)(C), which requires listed securities to maintain a minimum MVPHS of $15,000,000 (the “MVPHS Requirement”). The Company intends to monitor the market value of the Company’s listed securities and may, if appropriate, consider available options to regain compliance with the MVPHS Requirement.
Under Nasdaq Listing Rule 5810(c)(3)(D), the Company has a period of 180 calendar days (or until October 7, 2025) to regain compliance with the MVPHS Requirement. If at any time during this compliance period the Company’s MVPHS closes at $15,000,000 or more for a minimum of ten consecutive business days, Nasdaq will provide the Company with written confirmation of compliance and this matter will be closed. In the event the Company does not regain compliance with the rule prior to the expiration of the compliance period, it will receive written notification that its securities are subject to delisting. At that time, the Company may appeal the delisting determination to a Nasdaq hearing’s panel.
The Company also received a letter from the Staff (the “MVLS Deficiency Notice”) notifying the Company that from February 20, 2025, to April 9, 2025, the Company’s Market Value of Listed Securities (“MVLS”) was below the minimum of $50 million required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Requirement”). An indicator will be displayed with quotation information related to the Company’s securities on NASDAQ.com and NASDAQTrader.com and may be displayed by other third-party providers of market data information, however, the Notice does not impact the listing of the Company’s securities on The Nasdaq Global Market at this time.
On June 23, 2025, the Company received net proceeds of $1,840 from the Second Convertible Note pursuant to the SEPA (see Note 12 of the unaudited condensed consolidated financial statements). The Second Convertible Note has a maturity date of November 13, 2025 (subject to earlier repayments based on Amortization Event described in Note 12) and incur interest at a rate of 0% (or 18% upon the occurrence of an uncured Event of Default). The Second Convertible Note was fully converted in July 2025 into 11,024,725 shares of Common stock.
On July 24, 2025, the Company issued the Advance Notice to YA in accordance with the terms of the SEPA, under which YA purchased from the Company 1,500,000 shares of common stock at an aggregate net purchase price of $385.
On July 25, 2025, the Company issued the Advance Notice to YA in accordance with the terms of the SEPA, under which YA purchased from the Company 1,000,000 shares of common stock at an aggregate net purchase price of $299.
On August 5, 2025, the Company issued the Advance Notice to YA in accordance with the terms of the SEPA, under which YA purchased from the Company 240,082 shares of common stock at an aggregate net purchase price of $50.
As of June 30, 2025, the Company had cash of $2,014. Due to its current liabilities, the cash available to the Company will not be sufficient to allow the Company to operate for at least 12 months from the date these financial statements are available for issuance. The future viability of the Company is largely dependent on its ability to raise additional capital to finance its operations. The Company expects to seek additional funding through equity and debt financings, collaboration agreements and research grants. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects.
34
Accordingly, based on the considerations discussed above, management has concluded there is substantial doubt as to the Company’s ability to continue as a going concern within one year after the date the condensed consolidated financial statements are issued. The unaudited condensed consolidated financial statements included elsewhere in this filing do not include any adjustments with respect to the carrying amounts of assets and liabilities and their classification that might result from the outcome of this uncertainty.
Future Funding Requirements
We expect our expenses to increase in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials of our product candidates. In addition, subsequent to the Closing of the Merger, we anticipate the significant general and administrative costs associated with operating as a public company. The timing and amount of our operating expenditures will depend largely on:
| ● | the scope, number, initiation, progress, timing, costs, design, duration, any potential delays, and results of clinical trials and nonclinical studies for our current or future product candidates, particularly the planned Phase 1/2 clinical trial for ABP-102, focusing on HER2+ breast and gastric cancers, as well as Phase 1 clinical trials for ABP-201 for the treatment of Wet AMD; |
| ● | the clinical development plans we establish for our product candidates; |
| ● | the number and characteristics of product candidates and programs that we develop or may in-license; |
| ● | the outcome, timing and cost of regulatory reviews, approvals or other actions to meet regulatory requirements established by the FDA and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies for our product candidates than those that we currently expect; |
| ● | our ability to obtain marketing approval for our product candidates; |
| ● | the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights covering our product candidates, including any such patent claims and intellectual property rights that we have licensed pursuant to the terms of its license agreement; |
| ● | our ability to maintain, expand and defend the scope of its intellectual property portfolio, including the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us or our product candidates; |
| ● | the cost and timing of completion of commercial-scale outsourced manufacturing activities with respect to our product candidates; |
| ● | our ability to establish and maintain licensing, collaboration or similar arrangements on favorable terms and whether and to what extent we retain development or commercialization responsibilities under any new licensing, collaboration or similar arrangement; |
| ● | the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize its products on our own; |
| ● | the success of any other business, product or technology that we acquire or in which we invest; |
| ● | the costs of acquiring, licensing or investing in businesses, product candidates and technologies; |
| ● | our need and ability to hire additional management and scientific and medical personnel; |
| ● | the costs to operate as a public company in the United States, including the need to implement additional financial and reporting systems and other internal systems and infrastructure for our business; |
| ● | market acceptance of our product candidates, to the extent any are approved for commercial sale; and |
| ● | the effect of competing technological and market developments. |
35
Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, and marketing, distribution or licensing arrangements with third parties. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our ownership interest may be materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect the rights of our stockholders and the rights of the stockholders of the combined organization following the Closing of the Merger. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specified actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, scale back or discontinue the development and commercialization of one or more of our product candidates or delay our pursuit of potential in-licenses or acquisitions.
The following table summarizes our cash flows for the six months ended June 30, 2025 and 2024:
| For the Six Months Ended June 30, | ||||||||||||||||
| 2025 | 2024 | Change | % | |||||||||||||
| Net cash used in operating activities | $ | (3,105 | ) | $ | (4,218 | ) | $ | 1,113 | -26 | % | ||||||
| Net cash used in investing activities | $ | - | $ | - | $ | - | 0 | % | ||||||||
| Net cash provided by financing activities | $ | 2,142 | $ | 3,559 | $ | (1,417 | ) | -40 | % | |||||||
Net cash used in operating activities for the six months ended June 30, 2025, decreased by $1.1 million as compared to the six months ended June 30, 2024. The decrease in cash used in operating activity is primarily due to the timing of payments, with approximately $1.3 million increase in accounts payable, partially offset by approximately $0.2 million increase in prepaid expenses for the six months ended June 30, 2025 as compared to the same period in the prior year.
Net cash provided by financing activities decreased by $1.4 million for the six months ended June 30, 2025, as compared to the six months ended June 30, 2024. During the six months ended June 30, 2025, the Company received proceeds of $1.8 million from the issuance of convertible notes and proceeds of $0.5 million from a note payable for an insurance premium financing agreement. During the six months ended June 30, 2024, the Company received proceeds of $3.8 million from the issuance of notes payable to related parties, partially offset by approximately $0.2 million in merger related costs.
Critical Accounting Policies and Estimates
This discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported expenses and net loss incurred during the reporting periods. Our estimates are based on our historical experience and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
Recent Accounting Pronouncements
See Note 2, Summary of Significant Accounting Policies of the Notes to the Unaudited Condensed Consolidated Financial Statements for a discussion of recent accounting pronouncements.
36
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Not required for smaller reporting companies.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Management, under the supervision and with the participation of the Company’s principal executive and principal financial officer, have conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)). Disclosure controls and procedures are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
Based on this evaluation, our principal executive officer and principal financial officer has concluded that during the quarter ended June 30, 2025, our disclosure controls and procedures were not effective due to the material weaknesses described below.
Remediation Efforts to Address a Previously Identified Material Weakness in Internal Control over Financial Reporting
As described in Item 9.A Controls and Procedures of our Annual Report, management has identified material weaknesses in its internal control over financial reporting. A material weakness is a deficiency, or combination of deficiencies, in a company’s internal control over financial reporting such that there is a reasonable possibility that a material misstatement of its annual or interim financial statements will not be prevented or detected on a timely basis. The Company identified material weaknesses in its internal controls related to the Company having inadequate segregation of duties over internal wire transfer authorization and access to bank accounts, inadequate existing control to ensure timely identification and evaluation of contractual obligations such as license agreements and failing to design and maintain formal written policies and procedures regarding internal controls over financial reporting.
To address these material weaknesses, management, under the oversight of the audit committee, has devoted, and plans to continue to devote, significant effort and resources to the remediation and improvement of its internal control over financial reporting:
| ● | The Company redesigned and implemented proper authorization procedures and access controls with respect to wire transfers and bank account access. |
| ● | The Company is in the process of designing formal written policies and procedures regarding internal controls over financial reporting. |
| ● | The Company is in the process of implementing enhanced review processes to ensure timely identification of appropriate accounting related to all contractual obligations and license agreements. |
Such material weaknesses and control deficiencies will not be remediated until the Company’s remediation plan has been fully implemented, and it has concluded that its internal controls are operating effectively for a sufficient period of time.
We can offer no assurance that these initiatives will ultimately have the intended effects.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting (as defined by Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the most recently completed quarter, that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
37
PART II - OTHER INFORMATION
Item 1. Legal Proceedings
None
Item 1A. Risk Factors
Factors that could cause our actual results to differ materially from those in this Quarterly Report are any of the risks described in our Annual Report. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. As of the date of this Quarterly Report, except as disclosed below, there have been no material changes to the risk factors disclosed in our Annual Report filed with the SEC.
Our failure to meet Nasdaq’s continued listing requirements could result in a delisting of our shares.
On April 2, 2025, the Company received written notice (the “Notice”) from the Listing Qualifications Department Staff of Nasdaq (the “Staff”) notifying the Company that, based on the closing bid price of the Company’s Common Stock for the last 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Stock Market LLC. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”), and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement exists if the deficiency continues for a period of 30 consecutive business days. Pursuant to the Nasdaq Listing Rules, the Company has been provided an initial compliance period of 180 calendar days to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Company’s Common Stock must be at least $1.00 per share for a minimum of 10 consecutive business days prior to September 29, 2025. If the Company does not regain compliance by September 29, 2025, the Company may be eligible for an additional 180 calendar day compliance period. If the Company does not regain compliance within the compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company’s Common Stock will be subject to delisting.
On April 10, 2025, the Company received two letters from the Staff. One letter (the “MVPHS Notice”) indicated that based upon Nasdaq’s review of the Company’s Market Value of Publicly Held Shares (“MVPHS”) for the last 30 consecutive business days prior to the date of the MVPHS Notice, the Company no longer meets the requirements of Nasdaq Listing Rule 5450(b)(2)(C), which requires listed securities to maintain a minimum MVPHS of $15,000,000 (the “MVPHS Requirement”). The Company intends to monitor the market value of the Company’s listed securities and may, if appropriate, consider available options to regain compliance with the MVPHS Requirement. Under Nasdaq Listing Rule 5810(c)(3)(D), the Company has a period of 180 calendar days (or until October 7, 2025) to regain compliance with the MVPHS Requirement. If at any time during this compliance period the Company’s MVPHS closes at $15,000,000 or more for a minimum of ten consecutive business days, Nasdaq will provide the Company with written confirmation of compliance and this matter will be closed. In the event the Company does not regain compliance with the rule prior to the expiration of the compliance period, it will receive written notification that its securities are subject to delisting. At that time, the Company may appeal the delisting determination to a Nasdaq hearing’s panel.
The Company also received a letter from the Staff (the “MVLS Deficiency Notice”) notifying the Company that from February 20, 2025, to April 9, 2025, the Company’s Market Value of Listed Securities (“MVLS”) was below the minimum of $50 million required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has 180 calendar days from the date of the MVLS Deficiency Notice, or until October 7, 2025 (the “Compliance Date”), to regain compliance with respect to the MVLS Requirement. The MVLS Deficiency Notice states that to regain compliance with the MVLS Requirement, the Company’s MVLS must close at $50 million or more for a minimum of ten consecutive business days during the compliance period ending on the Compliance Date.
38
The Notice, MVPHS Notice and MVLS Deficiency Notice have no immediate effect on the listing of the Company’s Common Stock, and the Company’s Common Stock continues to trade on the Nasdaq Global Market under the symbol “ABP.”
If we are unable to regain compliance with the Minimum Bid Price Rule, MVPHS Requirement and MVLS Requirement, and maintain compliance with other continued listing requirements, Nasdaq may take steps to delist our shares. Such a delisting would likely have a negative effect on the price of our shares and would impair your ability to sell or purchase our shares when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our shares to become listed again, stabilize the market price or improve the liquidity of our shares, prevent our shares from dropping below Nasdaq’s Minimum Bid Price Requirement or prevent future non-compliance with Nasdaq’s listing requirements.
If Nasdaq delists our securities from trading on its exchange and we are not able to list our securities on another national securities exchange, we expect our securities could be quoted on an over-the-counter market. If this were to occur, we could face significant material adverse consequences, including:
| ● | a limited availability of market quotations for our securities; |
| ● | reduced liquidity for our securities; |
| ● | a determination that our Common Stock is “penny stock” which will require brokers trading in the Common Stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities; |
| ● | a limited amount of news and analyst coverage; and |
| ● | a decreased ability to issue additional securities or obtain additional financing in the future. |
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
(a)
Convertible Notes
On October 30, 2024, the Company and Abpro Corporation entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, Ltd. (“YA”). Subject to the satisfaction of the conditions set forth in the SEPA, YA was to advance to the Company the aggregate principal amount of $5.0 million (the “Pre-Paid Advance”), which was to be evidenced by convertible promissory notes. The Pre-Paid Advance was to be funded in two tranches: (i) the first tranche, in the principal amount of $3.0 million, was advanced the first trading day following the Closing of the Merger, and (ii) the second and final tranche, in the principal amount of $2.0 million was to be advanced on the later of (a) the second trading day following the effectiveness of the initial registration statement filed pursuant to the registration rights agreement and (b) the second trading day receipt of the required shareholder approval to issue shares of the Company’s common stock in excess of the Exchange Cap (as defined in the SEPA).
39
On November 14, 2024, pursuant to the SEPA, the Company entered into a Convertible Promissory Note (the “First Convertible Note”) for $3.0 million, issued with an 8% original issue discount, and received net proceeds of approximately $2.8 million. On June 23, 2025, pursuant to the SEPA, the Company entered into a Convertible Promissory Note (the “Second Convertible Note”) and, together with the First Convertible Note the “Convertible Notes”) for $2.0 million, issued with an 8% original issue discount and received net proceeds of approximately $1.8 million. In the SEPA, YA represented to the Company, among other things, that it is an “accredited investor” (as such term is defined in Rule 501(a) of Regulation D under the Securities Act of 1933, as amended (the “Securities Act”)). The Convertible Notes were issued and sold by the Company to YA in reliance upon the exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act.
During the quarter ended June 30, 2025, the Company issued YA an aggregate of 15,419,428 shares of common stock in connection with the conversion of a portion of outstanding and unpaid balance of the Convertible Notes, in the aggregate amount of $3.0 million. In connection with the foregoing, the Company relied upon the exemption from registration provided under Section 4(a)(2) under the Securities Act for transactions not involving a public offering.
(b) Not applicable.
(c) None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
None.
Item 5. Other Information
40
Item 6. Exhibits
The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.
| * | Filed or furnished herewith. |
41
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ABPRO HOLDINGS, INC. | ||
| Date: August 13, 2025 | By: | /s/ Miles Suk |
| Name: | Miles Suk | |
| Title: | Chief Executive Officer | |
| (Principal Executive Officer and Principal Financial and Accounting Officer) | ||
42
Exhibit 31.1
CERTIFICATION PURSUANT TO RULE 13A-14(A)
UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Miles Suk, certify that:
| 1. | I have reviewed this quarterly report on Form 10-Q of Abpro Holdings, Inc.; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and |
| b) | (Paragraph omitted pursuant to Exchange Act Rules 13a-14(a) and 15d-15(a)); |
| c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
| a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
| b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: August 13, 2025
| /s/ Miles Suk | |
| Miles Suk | |
| Chief Executive Officer | |
| (Principal Executive Officer and Principal Financial and Accounting Officer) |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Abpro Holdings, Inc. (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2025, as filed with the Securities and Exchange Commission (the “Report”), I, Miles Suk, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
| 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Dated: August 13, 2025
| /s/ Miles Suk | |
| Miles Suk | |
| Chief Executive Officer | |
| (Principal Executive Officer and Principal Financial and Accounting Officer) |